Sponsor
Department of Defense (DoD), managed by the office of Congressionally Directed Medical Research Programs (CDMRP).
Program
Amyotrophic Lateral Sclerosis Research Program (ALSRP)
For More Information
Description
The Department of Defense (DoD) managed by the office of Congressionally Directed Medical Research Programs (CDMRP) has recently released Fiscal Year 2020 (FY20) funding opportunities for the Amyotrophic Lateral Sclerosis Research Program (ALSRP):
- Clinical Development Award
- The intent of the FY20 ALSRP Clinical Development Award mechanism is to support studies leveraging human-based ALS resources to enrich clinical trials, in addition to projects designed to optimize components of current ALS clinical care. Leveraging can refer to the use of existing well-characterized and highly curated resources, or collaboration with ongoing clinical research to amplify potential gains in knowledge. Analysis of results and/or biosamples collected under these projects should be made broadly available through deposition in existing publicly available curated repositories and data platforms.
- Therapeutic Idea Award
- The FY20 ALSRP Therapeutic Idea Award supports hypothesis-driven therapeutic development and is designed to promote new ideas aimed at drug or treatment discovery that are still in the early stages of development. Development and/or modification of preclinical model systems or the application of high-throughput screens to define or assess lead compounds for ALS treatment may also be proposed. All research projects should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality. Preliminary data are not required. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data, but on the innovative approach.
- Therapeutic Development Award
- The FY20 ALSRP Therapeutic Development Award supports research ranging from validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Preliminary data are required, including efficacy in at least one ALSrelevant model system with a lead molecule/class of compounds. The availability of validated biomarkers or biomarker development/characterization, in parallel to the main therapeutic effort and for use in eventual clinical trials, is a critical component of the FY20 ALSRP Therapeutic Development Award. Applicants with limited ALS experience are strongly encouraged to include collaborators with substantial expertise in the relevant ALS model systems, endpoints, and pathophysiology
Detailed descriptions of funding opportunities, evaluation criteria, and submission requirements can be found in the specific Program Announcements.
Eligibility
Eligible non-DoD organizations may apply. Examples of extramural organizations include academic institutions, biotechnology companies, foundations, Federal Government organization other than the DoD, and research institutes. Independent investigators at all academic levels (or equivalent) are eligible to be named as PI.
Maximum Project Value
Clinical Development Award
The anticipated direct costs budgeted for the entire period of performance for an FY20 ALSRP Clinical Development Award will not exceed $300,000.
Therapeutic Idea Award
The anticipated direct costs budgeted for the entire period of performance for an FY20 ALSRP Therapeutic Idea Award will not exceed $500,000. The anticipated direct costs budgeted for the entire period of performance for an FY20 ALSRP Therapeutic Idea Award with the Therapeutically Relevant Biomarker Option will not exceed $600,000
Therapeutic Development Award
The anticipated direct costs budgeted for the entire period of performance will not exceed $1,000,000. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the Government exceeding $1,000,000 direct costs or using an indirect cost rate exceeding the organization’s negotiated rate.
Project Duration
Clinical Development Award
The maximum period of performance is 2 years.
Therapeutic Idea Award
The maximum period of performance is 2 years
Therapeutic Development Award
The maximum period of performance is 3 years.
Deadlines
If College-level review is required, your College will communicate its earlier internal deadlines.
| Type | Date | Notes |
|---|---|---|
External Deadline | A pre-application must be submitted through the eBRAP portal (registration is required). | |
Internal Deadline | Applicants invited to Full Application must submit a copy of their Full Application, along with budget and signed OR-5 to research.services@uoguelph.ca. | |
External Deadline | Invited applicants must submit their application directly via Grants.gov |
How to Apply
Submission is a two-step process requiring both pre-application submission and full application submission. All pre-applications must be submitted through eBRAP. Full applications from extramural organizations (non-DoD organizations) must be submitted through Grants.gov. Intramural DoD organizations may submit full applications to either eBRAP or Grants.gov.
Refer to the General Application Instructions, Section II.A. for registration and submission requirements for eBRAP and Grants.gov. For detailed information on the submission process, refer to Section II.D. of the Program Announcement/Funding Opportunity.
Attachment(s)
| Attachment | Size |
|---|---|
 ALSRP Award Mechanisms | 35.75 KB |
| ALSRP General Application Instructions | 553.78 KB |
| Therapeutic Development Award - Program Announcement | 269.11 KB |
| Therapeutic Idea Award - Program Announcement | 268.01 KB |
| Clinical Development Award - Program Announcement | 247.37 KB |